

Bispecific anti-mouse TIGIT x anti-mouse CD25 (IL-2R α)

Attention: Use of this product constitutes an agreement to Bio X Cell's Terms and Conditions which are included with this product in print and can also be found at <https://bioxcell.com/terms-and-conditions>.

Lot Specific Information

Lot Number: Lot Specific*
Volume: Lot Specific*
Concentration: Lot Specific* (generally 4 to 11 mg/ml) *
Total Protein: Lot Specific*

*This information will be noted on the certificate of analysis that ships with this product.

Product Information

Catalog Number: CPB532
Clone: derived from clones 1G9 and 7D4
Isotype: Mouse IgG2a, κ
Recommended Isotype Control(s): RecombiMAb mouse IgG2a isotype control, unknown specificity
Recommended Dilution Buffer: InVivoPure pH 7.0 Dilution Buffer
Reported Applications: ELISA
For information on in-vivo applications, please contact technicalservice@bioxcell.com
Formulation: PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin: ≤ 0.5 EU/mg (≤ 0.0005 EU/ μ g)
Determined by LAL assay
Purity: $\geq 95\%$
Determined by SDS-PAGE
Sterility: 0.2 μ m filtration
Production: Purified from mammalian cell supernatant in an animal-free facility
Purification: Protein A
RRID:
Molecular Weight: 145.4 kDa

Murine Pathogen Test Results

Mouse Norovirus: Negative, Mouse Parvovirus: Negative, Mouse Minute Virus: Negative, Mouse Hepatitis Virus: Negative, Reovirus Screen: Negative, Lymphocytic Choriomeningitis virus: Negative, Lactate Dehydrogenase-Elevating Virus: Negative, Mouse Rotavirus: Negative, Theiler's Murine Encephalomyelitis: Negative, Ectromelia/Mousepox Virus: Negative, Hantavirus: Negative, Polyoma Virus: Negative, Mouse Adenovirus: Negative, Sendai Virus: Negative, Mycoplasma Pulmonis: Negative, Pneumonia Virus of Mice: Negative, Mouse Cytomegalovirus: Negative, K Virus: Negative

Description

CPB532 is a 1+1 bivalent bispecific designed to simultaneously target mouse T cell immunoreceptor with Ig and ITIM domains (TIGIT) and mouse CD25 (IL-2R α). CPB532 contains the murine IgG2a constant region to reduce immunogenicity and the formation of anti-drug antibodies (ADAs) in mouse models. This bispecific was designed to selectively deplete intratumoral Tregs that co-express both CD25 and TIGIT, while sparing most peripheral Tregs and activated effector T cells creating a stronger anti-tumor immune response. CD25 targeting helps identify activated, highly suppressive Tregs in the tumor microenvironment, where CD25 expression is enriched on the most immunosuppressive subset. TIGIT targeting adds tumor selectivity because TIGIT is also enriched on tumor Tregs and marks a suppressive, activated phenotype. Anti-TIGIT x anti-CD25 bispecifics work by co-targeting a double-positive intratumoral Treg population to selectively remove suppressive cells and restore anti-tumor immunity.

Storage

Store at the stock concentration at 4°C . **Do not freeze.**

It is not uncommon for a floccule or precipitate to appear during storage. The floccule is typically buffer salts precipitating out of solution or a small bit of protein aggregation. For information on how to remove floccules or precipitates see our FAQ's at <https://bioxcell.com/faqs>.

Protocol Information

Since applications vary, each investigator should use the application references as a guide to help estimate the appropriate dose or concentration. The dose or concentration can be further optimized experimentally in a dose response or titration experiment.

Application References

For a complete list of references, visit [?utm_source=cr9k1b#tab_references](https://bioxcell.com/?utm_source=cr9k1b#tab_references) or scan the QR code below.



Bio X Cell, LLC

<https://bioxcell.com>

+1-866-787-3444

customerservice@bioxcell.com

Conditions: For research use only. Not for use in diagnostic or therapeutic procedures.

Not for resale.

Bio X Cell, Bio X Cell logo, and all other trademarks are the property of Bio X Cell, LLC © 2026 Bio X Cell, LLC